Cabrera JP, Caselli BE, Gallardo AA, Molina HE

Language: Spanish
References: 11
Page: 39-44
PDF size: 68.70 Kb.

ABSTRACT

Introduction: The esophagic cancer of the upper third represents the 15% of the esophagic cancer and it is one of the tumours with worst prediction, because the therapeutic alternatives are restricts and its global survival are very low. Objective: Know and communicate the reality of esophagic cancer of the upper third between the years 2002 and 2006 at the Hospital Guillermo Grant Benavente, Concepcion, Chile. Material and Method: Transversal descriptive study, we studied 13 patients by sex, age, deep of penetration, histology, treatment. Analysis of survival by Kaplan-Meier method. Results: Males 10 (77%) and females 3 (23%). Age average 67 years old (49-90). In 12 patients (92%) at the moment of diagnosis was advanced cancer, and one patient (8%) did not any study of the tumour. Histology: Squamous 12(92%) and adenosquamous 1(8%). Treatment. 8 patients (62%) did only treatment to alleviate intention and in 5(38%) reject or non treatment. Average of survival is 3 months and to 9 months of diagnosis it is of 0%. Conclusion: In our center the upper third esophagic cancer is diagnosed out of phase to healing treatment, and the waited survival for our patients it doesn’t overcome one year of survival in the 100% of the patients. It is necessary to give an incentive to early diagnosis and we have got to work as a team. [Experience On Upper Third Esophagic Cancer At The Hospital Guillermo Grant Benavente, Concepcion, Chile.

REFERENCES

1. Jamieson G, Mathew G, Watson D, Myers J. An overview of the treatment of esophageal cancer in the 20th century: The experience of the West. Can J Gastroent 1998; 52 (A): 147.

2. BRAGHETTO I. Cáncer de esófago In: Arratzoa, Jorge. Cáncer de esófago. Santiago: Mediterráneo; 1997. 114-40.

3. RICE TH W, ZUCCARO G, ADELSTEIN D, RYBICKI L, BLACKSTONE et al. Esophageal carcinoma: Depth of tumor invasion is predictive of regional lymphonode status. The therapeutic and pronostic implications. Can J Gastroent 1998:12 (B): 4-15 (A22-23).

4. ISHIBASHI S, SHINEBA L, HOSHIDA T. Do the number of metastatic lymph node decide pronostic of esophageal cancer. Can J Gastroent 1998; 12(B) 16 (A 25).

5. BRAGHETTO I, CSNEDES A, CORNEJO A, AMAT J, CARDEMIL G et al. Sobrevida de pacientes con cáncer de esófago sometidos a esofagectomía total torácica. Rev Méd Chile 2000; 128: 64-74.

6. VENTURELLI A, SANCHEZ A, CARDEMIL B. Cáncer de esófago. Sobrevida a 10 años plazo. Rev Chi Cir 2001; 53: 241-5.

7. ALVAREZ R, SEGUEL E, BETANCUR C, ZUÑIGA C, GALLARDO A et al. Recidiva tumoral en tubo gástrico en esofagectomías por carcinoma. Rev Chil Cir 2002; 54: 49-52.

8. LAW S, FOK M, WONG J. Pattern of recurrence after oesophageal resection for cancer: clinical implications. Br J Surg 1996; 83: 107-11.

9. VENTURELLI A, SOTO S, DÍAZ J, CARDEMIL B, SÁNCHEZ A et al. Cáncer de esófago, tratamiento en el Hospital Clínico Regional de Valdivia durante el período 1982-2001. Rev Chil Cir 2003; 55: 381-384.

10. JAE III Z, YOUNG H, HEE JONG B, JONG H. Longterm results of surgical treatment for esophageal cancer (10 years experience). Can J Gastroent 1998; 12 (B): 13 (A 18).

11. NISHIMAKI T, SUZUKI T, KONDO T, KUWABARA SH, MUSHA N et al. Short and long term results after extended radical esophagectomy for esophageal carcinoma. Can J Gastroent 1998; 12(B) 130 (A415).